ABBV AbbVie, Inc.

Price (delayed)

$94.68

Market cap

$167.09B

P/E Ratio

20.06

Dividend/share

$4.61

EPS

$4.72

Enterprise value

$248.51B

Sector: Healthcare
Industry: Drug Manufacturers - General
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Highlights

ABBV's revenue is up by 11% year-on-year and by 6% since the previous quarter
ABBV's P/E is 6% below its 5-year quarterly average of 21.4 and 4.9% below its last 4 quarters average of 21.1
The company's net income has surged by 69% YoY but it fell by 18% QoQ
The EPS has soared by 68% YoY but it has contracted by 17% from the previous quarter
The debt has surged by 135% year-on-year and by 30% since the previous quarter
The quick ratio has plunged by 80% from the previous quarter and by 9% YoY

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.76B
Market cap
$167.09B
Enterprise value
$248.51B
Valuations
Price to earnings (P/E)
20.06
Price to book (P/B)
9.51
Price to sales (P/S)
4.3
EV/EBIT
26.44
EV/EBITDA
19.84
EV/Sales
6.86
Earnings
Revenue
$36.23B
EBIT
$9.4B
EBITDA
$12.52B
Free cash flow
$14.12B
Per share
EPS
$4.72
Free cash flow per share
$8.57
Book value per share
$9.96
Revenue per share
$22
TBVPS
$18.46
Balance sheet
Total assets
$149.53B
Total liabilities
$134.8B
Debt
$87.43B
Equity
$14.71B
Working capital
-$3.39B
Liquidity
Debt to equity
5.94
Current ratio
0.86
Quick ratio
0.58
Net debt/EBITDA
6.5
Margins
EBITDA margin
34.6%
Gross margin
73.6%
Net margin
19.2%
Operating margin
30.2%
Efficiency
Return on assets
7.1%
Return on equity
N/A
Return on invested capital
14.7%
Return on capital employed
7.5%
Return on sales
25.9%
Dividend
Dividend yield
4.87%
DPS
$4.61
Payout ratio
97.7%

ABBV stock price

How has the AbbVie stock price performed over time

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$36.23B
Gross profit
$26.65B
Operating income
$10.93B
Net income
$6.96B
Gross margin
73.6%
Net margin
19.2%
The company's net income has surged by 69% YoY but it fell by 18% QoQ
The operating income has soared by 53% YoY but it has contracted by 20% from the previous quarter
The net margin has surged by 52% year-on-year but it has declined by 23% since the previous quarter
The operating margin rose by 39% year-on-year but it has declined by 24% since the previous quarter

Valuation

What is AbbVie stock price valuation
P/E
20.06
P/B
9.51
P/S
4.3
EV/EBIT
26.44
EV/EBITDA
19.84
EV/Sales
6.86
The EPS has soared by 68% YoY but it has contracted by 17% from the previous quarter
ABBV's P/E is 6% below its 5-year quarterly average of 21.4 and 4.9% below its last 4 quarters average of 21.1
ABBV's P/S is 13% above its last 4 quarters average of 3.8 and 2.4% above its 5-year quarterly average of 4.2
ABBV's revenue is up by 11% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is AbbVie business performance
The ROS has soared by 69% YoY but it has contracted by 17% from the previous quarter
AbbVie's return on assets has decreased by 38% QoQ but it has increased by 2.9% YoY
AbbVie's ROIC has decreased by 29% from the previous quarter but it has increased by 13% YoY

Dividends

What is ABBV's dividend history
DPS
$4.61
Dividend yield
4.87%
Payout ratio
97.7%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 11% higher than its total liabilities
AbbVie's total assets has surged by 162% YoY and by 64% QoQ
The total liabilities has surged by 105% year-on-year and by 37% since the previous quarter
The debt has surged by 135% year-on-year and by 30% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.